A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection

Latin American Cooperative Oncology Group369 enrolled

Overview

Due to the scarcity of data on prognostic and predictive influence on CCA, epidemiological studies evaluating these factors need to be developed in patients with CCA. Therefore, the investigators want to evaluate the profile of patients in the real world and from various parts of the world, describing prognostic factors such as CD4 dosage, time of HIV infection, evaluation of viral load, diagnosis of AIDS, geographic region of diagnosis and treatment, clinical staging, medications concomitant with QRT (risk of drug interactions), comorbidities (possible impact on dose-intensity), use of HAART, time of use of HAART, radiotherapy modality (conventional 3D vs Modulated Beam Intensity \[IMRT\], response to Nigro vs CTII regimens, as well as comparing clinical outcomes with patients without HIV infection.

Study Type

OBSERVATIONAL

Enrollment

369

Conditions

Anal Squamous Cell Carcinoma HIV Infections

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients 18 years of age or older * Confirmed histological diagnosis of anal canal squamous cell carcinoma. Basaloid subtype is accepted * Have underundered serological test for HIV infection * Any clinical stage Exclusion Criteria: * Lack of data on treatments and clinical outcomes

Locations (11)

Hospital de Gastroenterología Carlos Bonorino Udaondo

Buenos Aires, Buenos Aires, Argentina

INCA - Instituto Nacional de Câncer

Rio de Janeiro, Rio de Janeiro, Brazil

HUOL - Hospital Universitário Onofre Lopes da UFRN

Natal, Rio Grande do Norte, Brazil

Liga Norte Riograndense Contra o Câncer

Natal, Rio Grande do Norte, Brazil

CEPON - Centro de Pesquisas Oncológicas

Florianópolis, Santa Catarina, Brazil

Hospital de Amor de Barretos

Barretos, São Paulo, Brazil

A.C. Camargo Cancer Center

São Paulo, São Paulo, Brazil

INCan - Instituto Nacional de Cancerología

Mexico City, Mexico City, Mexico

INEN - Instituto Nacional de Enfermedades Neoplásicas

Lima, Peru, Peru

Oncosalud AUNA

Lima, Peru, Peru

...and 1 more locations

Outcomes

Primary Outcomes

Median disease-free survival

Defined as time from Day 1 from initiation of treatment (or definition of exclusive supportive care) to tumor death or recurrence. Disease-free survival at 3 years after initiation of treatment: proportion of patients free of local or metastatic disease at 3 years after treatment termination according to imaging tests (chest, abdomen and pelvis scans) and clinical examination of anal inspection

Time frame: 3 years

Complete clinical response

Absence of neoplasia on magnetic resonance imaging (preferred) or computed tomography of the pelvis and on clinical examination of anal inspection 6 months after the end of QRT or RT isolated

Time frame: 6 months

Overall survival

Defined as the date from the D1 of treatment (or exclusive supportive care) to death from any cause; living patients at the time of the analysis will be censored.

Time frame: From first date of treatment to date of death from any cause, assessed up to 3 years.